Antengene Corporation Limited (HK:6996) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Antengene Corporation Limited has received approval from South Korea’s Ministry of Food and Drug Safety for a supplemental New Drug Application for XPOVIO, marking its third indication. This approval allows the use of XPOVIO in combination with other drugs to treat multiple myeloma, further strengthening Antengene’s position in the global biopharmaceutical market. The company is known for its innovative treatments targeting hematologic malignancies and solid tumors.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.